Vetoryl Capsules is a drug owned by DECHRA, LTD. It is protected by 1 US drug patent filed in 2024. All patents have expired. Details of Vetoryl Capsules’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US9283235 | Active | |
Vetoryl Capsules Petitions
Details of Vetoryl Capsules's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Norbrook Laboratories Limited | Approved | 18 May, 2023 | The proposed change is for an oral suspension ; the RLNAD is approved as capsules in 5 mg, 10 mg, 30 mg, 60 mg, and 120 mg capsule strengths. |
About Vetoryl Capsules
Vetoryl Capsules is a drug
owned by DECHRA, LTD.
Vetoryl Capsules uses
Trilostane as the active
ingredient.
Active Ingredient:
Vetoryl Capsules uses
Trilostane as the active ingredient.
Check out other Drugs and Companies using
Trilostane ingredient.